Drug Profile

Antisense oligonucleotide therapeutic - Creyon Bio

Latest Information Update: 13 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Creyon Bio
Class Antisense oligonucleotides
Mechanism of Action Gene silencing; TNPO2 protein expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Clinical Phase Unknown Neurological disorders

Most Recent Events

07 May 2024 Efficacy and adverse events data from a clinical trial in Neurological disorders released by Creyon Bio
31 Aug 2023 Clinical trials in Neurological disorders in USA (Intrathecal)
31 Aug 2023 Preclinical trials in Neurological disorders in USA (Intrathecal) prior to March 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com